Clinical Trial

Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma.

Study acronym: SBRT/IL-2
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is compare the response rates in patients with metastatic melanoma treated with high-dose IL-2 to patients treated with high-dose IL-2 along with radiation therapy.
Protocol Amendment History 17 amendments
This ClinicalTrials.gov record has been amended 17 times since 2011-08-12; most recent amendment 2026-04-07.
Status change: Recruiting → Active, Not Recruiting 2017-09-18
Trial Details
NCT Number NCT01416831
Lead Sponsor Providence Health & Services
Collaborators: Prometheus Laboratories
Conditions Metastatic Melanoma
Enrollment 44 participants
Start Date 2011-07-01
Primary Completion 2017-04-05 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-24